NCT04124601View on ClinicalTrials.gov

Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

March 15, 2024

Study Completion Date

March 15, 2024

Conditions
Rectal Cancer
Interventions
RADIATION

Chemoradiotherapy

Capecitabine tablet with fractionated radiotherapy

DRUG

Ipilimumab

Infusion

DRUG

Nivolumab

Infusion

Trial Locations (5)

1020

Hospital of St. John of God, Vienna

1090

Medical University of Vienna, Vienna

1210

Hospital North - Clinic Floridsdorf, Vienna

4010

Congregational Hospital Linz - Sisters of Mercy, Linz

Unknown

State Hospital Wiener Neustadt, Wiener Neustadt

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Johannes Laengle, MD, PhD

OTHER

NCT04124601 - Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer | Biotech Hunter | Biotech Hunter